Financials data is unavailable for this security.
View more
Year on year Daito Pharmaceutical Co Ltd had net income fall -8.47% from 3.60bn to 3.29bn despite a 3.98% increase in revenues from 45.10bn to 46.90bn. An increase in the cost of goods sold as a percentage of sales from 77.09% to 79.02% was a component in the falling net income despite rising revenues.
| Gross margin | 20.28% |
|---|---|
| Net profit margin | 6.32% |
| Operating margin | 7.66% |
| Return on assets | 3.90% |
|---|---|
| Return on equity | 6.27% |
| Return on investment | 5.08% |
More ▼
Cash flow in JPYView more
In 2024, cash reserves at Daito Pharmaceutical Co Ltd fell by 880.00m. However, the company earned 5.18bn from its operations for a Cash Flow Margin of 11.05%. In addition the company used 5.93bn on investing activities and also paid 183.00m in financing cash flows.
| Cash flow per share | 441.02 |
|---|---|
| Price/Cash flow per share | 4.85 |
| Book value per share | 3,400.43 |
|---|---|
| Tangible book value per share | 3,368.26 |
More ▼
Balance sheet in JPYView more
| Current ratio | 2.44 |
|---|---|
| Quick ratio | 1.29 |
| Total debt/total equity | 0.2335 |
|---|---|
| Total debt/total capital | 0.1891 |
More ▼
Growth rates in JPY
Year on year, growth in dividends per share increased 10.00% while earnings per share excluding extraordinary items fell by -7.67%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 1.75% |
|---|---|
| Div growth rate (5 year) | 11.67% |
| Payout ratio (TTM) | 28.95% |
| EPS growth(5 years) | -3.83 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -1.70 |
More ▼
